{"id":"W4379523514","doi":"10.1136/annrheumdis-2023-eular.2415","title":"POS0826 SAFETY PROFILE OF UPADACITINIB UP TO 6.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval","funders":"Chugai Pharmaceutical; Samsung; Genentech; Medac; H. Lundbeck A/S; Eisai; Astellas Pharma; Mylan; Gigtforeningen; Eli Lilly and Company; AstraZeneca; Kræftens Bekæmpelse; Daiichi-Sankyo; Teva Pharmaceutical Industries; Celgene; Biogen; Gilead Sciences; Kowa Company; Sanofi; Amgen; Pfizer","keywords":"Medicine; Adverse effect; Discontinuation; Internal medicine; Adalimumab; Rheumatoid arthritis; MedDRA; Population; Clinical trial; Pharmacovigilance","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008850654,0.0002238362,0.0006163233,0.0002545563,0.0002110138,0.0006569871,0.0002010856,0.0005313744,0.003704834],"category_scores_gemma":[0.001638503,0.0001190554,0.0007957004,0.0002836112,0.0002388212,0.0004077229,0.0002374821,0.001090896,0.001242168],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003441257,"about_ca_system_score_gemma":0.0004081392,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003969228,"about_ca_topic_score_gemma":0.0004779249,"domain_scores_codex":[0.9994779,0.0001339522,0.00004623484,0.0001012682,0.0001533342,0.00008731894],"domain_scores_gemma":[0.9992806,0.0002011937,0.0002286625,0.00004814913,0.0001360814,0.0001052851],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1350991,0.00258619,0.2413759,0.001498013,0.002202154,0.004138285,0.0005042318,0.006339644,0.07364943,0.001433839,0.0138576,0.5173157],"study_design_scores_gemma":[0.006391528,0.1215144,0.7359271,0.0007550661,0.004218805,0.01824236,0.0008515919,0.005426305,0.02506048,0.001411393,0.07997253,0.0002284855],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9804171,0.01013297,0.0004287477,0.0004957495,0.0001319912,0.00004416221,0.002078326,0.00004802447,0.006222829],"genre_scores_gemma":[0.9948548,0.001202591,0.0001020126,0.0003437288,0.00008223836,0.00002056322,0.001686534,0.000009754164,0.001697859],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003704834,"threshold_uncertainty_score":0.01239395,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02175560958648856,"score_gpt":0.2787929088595743,"score_spread":0.2570372992730857,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}